Novartis AG Cost Of Inventories Recognised As Expense During Period
Novartis AG (NVSEF) reported Cost Of Inventories Recognised As Expense During Period of $6.60 billion for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Cost of Sales
ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod · last filed 2026-02-04
| Period end | Cost Of Inventories Recognised As Expense During Period 12 month | Cost Of Inventories Recognised As Expense During Period 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.60B 20-F · filed 2026-02-04 | |
| 2024-12-31 | $6.30B 20-F · filed 2026-02-04 | |
| 2023-12-31 | $5.80B 20-F · filed 2026-02-04 | |
| 2022-12-31 | $5.20B 20-F · filed 2025-01-31 | $8.60B 20-F · filed 2023-02-01 |
| 2021-12-31 | $5.40B 20-F · filed 2024-01-31 | $8.80B 20-F · filed 2022-02-02 |
| 2020-12-31 | $8.50B 20-F/A · filed 2023-05-15 | |
| 2019-12-31 | $8.50B 20-F · filed 2022-02-02 | |
| 2018-12-31 | $8.30B 20-F · filed 2021-01-26 | $10.40B 20-F · filed 2019-01-30 |
| 2017-12-31 | $8.20B 20-F · filed 2020-01-29 | $10.30B 6-K · filed 2018-01-24 |
| 2016-12-31 | $10.30B 20-F · filed 2019-01-30 | |
| 2015-12-31 | $10.50B 6-K · filed 2018-01-24 |